Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Down 28.4% in January

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 28,845 shares, a decline of 28.4% from the December 31st total of 40,313 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 47,850 shares, the short-interest ratio is currently 0.6 days. Based on an average daily volume of 47,850 shares, the short-interest ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Stock Down 4.1%

Shares of NBTX stock opened at $21.00 on Friday. The stock has a fifty day moving average of $21.60 and a 200 day moving average of $16.76. Nanobiotix has a 52 week low of $2.95 and a 52 week high of $30.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $11.00.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.